Faes Farma SA (Faes Farma) discovers and develops pharmaceutical products. The company offers prescription drugs, generic drugs, over-the-counter (OTC) medications, skin-care treatments, food supplements, and raw materials for pharmaceutical use.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Faes Farma has undertaken significant R&D initiatives to enhance its position in the pharmaceutical industry. The company focuses on developing innovative and high-quality medicines, reinforcing its presence in principal therapeutic areas, and facilitating synergic commercial agreements with global pharmaceutical companies. The R&D efforts are directed towards achieving leadership in therapeutic areas where the company already has experience. Notable projects include the FAES2020 initiative, which aimed to develop 20 novel medicines by 2020, and the development of a new chemical entity in the allergy area. The company has achieved important milestones, such as the marketing of innovative medicines and approvals in various markets. Faes Farma's R&D activities are managed through three main units: IDI API (R&D+i for Active Ingredients), IDI Farma (R&D+i for Development and Pharmaceutical Technologies), and iDI Clínica (Clinical R&D+i). These units are responsible for the research and development of active ingredients, pharmaceutical technologies, and clinical research, respectively. The company also collaborates with teams in project management and R&D+i promotion. The company operates a research center staffed by around 70 highly qualified individuals. The text does not provide specific information on the number of patents, pipeline products, or major technology alliances. In FY2025, the company spent EUR4.8 million on R&D, which as a percentage of revenue, stood at 0.8% and declined by 15.6% YoY.